EMERALD MEDICAL APPLICATIONS CORP. (OTCMKTS:MRLA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On December 25, 2016, the Board of Directors of Emerald Medical
Applications Corp. (the Registrant) accepted the resignations of
Baruch Kfir and Chaim Hurvitz as members of the Registrant’s
Board of Directors. Copies of their letters of resignation are
attached hereto as Exhibits 17.5 and 17.6, respectively. Both
former directors informed the Board of Directors that they had no
disagreements with the operations, policies or practices of the
Registrant or its wholly-subsidiary Israeli subsidiary, Emerald
Medical Applications Ltd.
On the same date and in connection with the resignations of
Messrs. Kfir and Hurvitz, the Registrant appointed two new
members to the Board of Directors, Dr. Asher Shmulewitz and Alimi
Ahmed.
Dr. Ascher Shmulewitz, age 60: Dr. Shmulewitz has served
as chairman of Therapix Biosciences Ltd (OTCQB: THXBY and TASE:
THXBY), an Israel-headquartered emerging specialty pharmaceutical
company developing unique Cannabinoid technologies in treatment
of central nervous system (CNS) disorders, since January 2014 and
on the board of directors since February 2013. Dr. Shmulewitz, an
inventor and serial entrepreneur involved in biomedical
technologies, has originated over two dozen life science
companies including NeoVision Inc., Labcoat Medical Ltd., Arteria
Inc., Circulation Inc. and X-Cardia Inc., many of which companies
he led to successful exits through MA transactions with large
medical device companies. Dr. Shmulewitz has vast experience in
the venture capital arena as an investor, manager and
entrepreneur in dozens of companies and ventures as well as an
M.D. Dr. Shmulewitz co-founded San Francisco Science and the
Incumed Group for seed investments, and is the founder of
Medgenesis Partners Ltd., an Israeli private investment firm and
incubator that has invested in over a dozen ventures. Dr.
Shmulewitz previously held senior executive positions at Advanced
Technology Laboratories Inc. Dr. Shmulewitz received an MD degree
from The Technion Medical School and a Ph.D. degree in
Engineering from Tel Aviv University, Israel.
Alimi Ahmed, age 45: Mr. Ahmed is highly accomplished
investor and manager of several early-stage medical companies,
including Chairman and CEO of VaxilBio Ltd, an Israeli-based
company founded by Weizmann Institute scientists, Israel’s top
research university, in order to provide new approaches to
immunotherapy. Mr. Ahmed is also an investor of Therapixbio Ltd.
(OTCQB: THXBY and TASE: THXBY).
Item 9.01 Financial Statements and Exhibits
(b) The following documents are filed as exhibits to this current
report or incorporated by reference herein. Any document
incorporated by reference is identified by a parenthetical
reference to the SEC filing that included such document.
|
Exhibit No. |
Description |
| 17.5 |
Letter of Resignation of Baruch Kfir dated December 25, 2016, filed herewith. |
| 17.6 |
Letter of Resignation of Chaim Hurvitz dated December 25, 2016, filed herewith. |
About EMERALD MEDICAL APPLICATIONS CORP. (OTCMKTS:MRLA)
Emerald Medical Applications Corp. operates through its subsidiary, Emerald Medical Applications Ltd. (Emerald), which is a digital health company. Emerald is engaged in the development, sale and service of imaging solutions utilizing its DermaCompare software that it developed for use in derma imaging and analytics. Emerald’s DermaCompare solution allows dermatologists and other medical care professionals, using a set of total body photography (TBP), to capture sets of skin lesion images with, among other devices, digital cameras, camera-equipped smartphones or tablets. DermaCompare imaging solution is provided as a software platform for early detection of Melanoma for classification of dermatological lesions as published by the National Institute of Health (NIH) for analysis of moles. DermaCompare imaging software solution reads and extracts data from those images and in essence turns digital camera, camera-equipped smartphones and tablets into virtual scanning devices. EMERALD MEDICAL APPLICATIONS CORP. (OTCMKTS:MRLA) Recent Trading Information
EMERALD MEDICAL APPLICATIONS CORP. (OTCMKTS:MRLA) closed its last trading session 00.000 at 0.220 with 181,300 shares trading hands.
